DSpace Home
→
Browsing by Author

Browsing by Author "Cabuk, Devrim"

Now showing items 1-3 of 3

Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

Oktay, Esin; Levent, Mustafa; Gelincik, Hakan; Aktas, Gizem; Yumuk, Fulden; Koral, Lokman; Arpaci, Erkan; Keser, Murat; Alkan, Ali; Karci, Ebru; Karadurmus, Nuri; Degirmencioglu, Serkan; Turan, Merve; Uyeturk, Ummugul; Cabuk, Devrim; Avci, Nilufer; Toprak, Omer; Ergen, Arzu; Urvay, Semiha; Bayman, Evrim; Petekkaya, Emine; Nayir, Erdinc; Paydas, Semra; Yavuzsen, Tugba; Senler, Filiz Cay; Yaren, Arzu; Barutca, Sabri; Sahinler, Ismet; Ozyilkan, Ozgur; Tanriverdi, Ozgur (SPRINGER, 2020)

Cancer is one of the most common causes of death all over the World (Rahib et al. in Cancer Res 74(11):2913-2921, 2014; Silbermann et al. in Ann Oncol 23(Suppl 3):iii15-iii28, 2012). It is crucial to diagnose this disease ...
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Erol, Cihan; Sakin, Abdullah; Basoglu, Tugba; Ozden, Ercan; Cabuk, Devrim; Dogan, Mutlu; Oksuzoglu, Berna; Yildirim, Hasan Cagri; Oner, Irem; Eryilmaz, Melek Karakurt; Dulgar, Ozgecan; Aydin, Dincer (Scientific and Technological Research Council Turkey, 2022)

Background/aim: Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in ...
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

Ozdemir, Ozlem; Zengel, Baha; Yildiz, Yasar; Uluc, Basak Oyan; Cabuk, Devrim; Ozden, Ercan; Salim, Derya Kivrak; Paydas, Semra; Demir, Atakan (2022)

In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ...